Conv. Plasma
Nigella Sativa

All colchicine studies
Meta analysis
study COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 22% Improvement Relative Risk Colchicine  Gaitán-Duarte et al.  LATE TREATMENT  RCT Is late treatment with colchicine + rosuvastatin beneficial for COVID-19? RCT 314 patients in Colombia (August 2020 - March 2021) Lower mortality with colchicine + rosuvastatin (not stat. sig., p=0.38) Gaitán-Duarte et al., eClinicalMedicine, Jul 2021 Favors colchicine Favors control

Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial

Gaitán-Duarte et al., eClinicalMedicine, doi:10.1016/j.eclinm.2021.101242, NCT04359095
Jul 2021  
  Source   PDF   All   Meta
Colchicine for COVID-19
5th treatment shown to reduce risk in September 2020
*, now known with p = 0.00000018 from 53 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
RCT 633 hospitalized patients in Colombia, 153 treated with colchicine + rosuvastatin, not showing statistically significant differences in outcomes. Improved results were seen with the combination of emtricitabine/tenofovir disoproxil + rosuvastatin + colchicine. NCT04359095 (history).
Although the 22% lower mortality is not statistically significant, it is consistent with the significant 29% lower mortality [19‑39%] from meta analysis of the 42 mortality results to date.
risk of death, 22.0% lower, HR 0.78, p = 0.38, treatment 22 of 153 (14.4%), control 28 of 161 (17.4%), NNT 33, adjusted per study, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gaitán-Duarte et al., 10 Jul 2021, Randomized Controlled Trial, Colombia, peer-reviewed, 17 authors, study period 24 August, 2020 - 20 March, 2021, average treatment delay 10.0 days, dosage 0.5mg days 1-14, this trial uses multiple treatments in the treatment arm (combined with rosuvastatin) - results of individual treatments may vary, trial NCT04359095 (history).
This PaperColchicineAll
Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial
H G Gaitán-Duarte, C Álvarez-Moreno, C J Rincón-Rodríguez, N Yomayusa-González, J A Cortés, MD PhD J C Villar, MD J S Bravo-Ojeda, MD MSc A García-Peña, PhD W Adarme-Jaimes, PhD V A Rodríguez-Romero, MSc S L Villate-Soto, MD PhD G Buitrago, J Chacón-Sarmiento, MSc M Macias-Quintero, MSc C P Vaca, C Gómez-Restrepo, N Rodríguez-Malagón
eClinicalMedicine, doi:10.1016/j.eclinm.2021.101242
Background The use of rosuvastatin plus colchicine and emtricitabine/tenofovir in hospitalized patients with SARS-CoV-2 disease (COVID-19) has not been assessed. The objective of this study was to assess the effectiveness and safety of rosuvastatin plus colchicine, emtricitabine/tenofovir, and their combined use in these patients. Methods This was a randomized, controlled, open-label, multicentre, parallel, pragmatic study conducted in six referral hospitals in Bogot a, Colombia. The study enrolled hospitalized patients over 18 years of age with a confirmed diagnosis of COVID-19 complicated with pneumonia, not on chronic treatment with the study medications, and with no contraindications for their use. Patients were assigned 1:1:1:1. 1) emtricitabine with tenofovir disoproxil fumarate (FTC/TDF, 200/300 mg given orally for 10 days); 2) colchicine plus rosuvastatin (COLCH+ROSU, 0.5 mg and 40 mg given orally for 14 days); 3) emtricitabine with tenofovir disoproxil plus colchicine and rosuvastatin at the same doses and for the same period of time (FTC/TDF+COLCH+ROSU); or 4) the Colombian consensus standard of care, including a corticosteroid (SOC). The primary endpoint was 28-day all-cause mortality. A modified intention-to-treat analysis was used together with a usefulness analysis to determine which could be the best treatment. The trial was registered at NCT04359095
Author's contributions Hernando G. Gait an-Duarte: leader researcher, design, contact with external entities, data collection, analysis and interpretation, funding, writing; Carlos Alvarez-Moreno: design, data collection, analysis and interpretation; Carlos Javier Rincon: design, analysis and interpretation, writing; Nancy Yomayusa-Gonz alez: data collection, analysis and interpretation, writing; Jorge Alberto Cort es: data collection, analysis and interpretation, writing; Juan Carlos Villar: design, data collection; Juan Sebasti an Bravo-Ojeda: data collection; Angel Garc ıa-Peña: design, data collection; Wilson Adarme-Jaimes: design, data collection; Viviana Rodr ıguez-Romero: design, analysis and interpretation; Steffany L Villate-Soto: supervisory role; Giancarlo Buitrago: design, data analysis and interpretation, writing; Julio Chac on-Sarmiento: data collection; Mart ın Mac ıas-Quintero: data analysis; Claudia Patricia Vaca: analysis and interpretation; Carlos G omez-Restrepo: analysis and interpretation; Nelcy Rodr ıguez-Malag on: design, data collection, analysis and interpretation. Supplementary materials Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j. eclinm.2021.101242.
Austin, A Tutorial on Multilevel Survival Analysis: Methods, Models and Applications, Int Stat Rev
Bastard, Rosen, Zhang, Autoantibodies against type I IFNs in patients with life-threatening COVID-19, Science
Borba, Val, Sampaio, Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial, JAMA Netw Open
Chien, Anderson, Jockusch, Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19, J Proteome Res
Clososki, Soldi, Da Silva, Tenofovir Disoproxil Fumarate: New Chemical Developments and Encouraging in vitro Biological Results for SARS-CoV-2, J Braz Chem Soc
Deftereos, Giannopoulos, Vrachatis, Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial, JAMA Netw Open
Del Amo, Polo, Moreno, Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study, Ann Intern Med
Gravel, Opatrny, Shapiro, The intention-to-treat approach in randomized controlled trials: are authors saying what they do and doing what they say?, Clin Trials
Grifoni, Weiskopf, Ramirez, Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals, Cell
Group, Horby, Lim, Dexamethasone in Hospitalized Patients with Covid-19, N Engl J Med
Higgins, Thomas, Chandler, Cochrane handbook for systematic reviews of interventions
Horby, Campbell, Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Infectious Diseases, doi:10.1101/2021.05.18.21257267
Inspiration Investigatorssadeghipour, Talasaz, Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial, JAMA
Melchjorsen, Risør, Søgaard, Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells, J Acquir Immune Defic Syndr
Minz, Bansal, Kasliwal, Statins and SARS-CoV-2 disease: Current concepts and possible benefits, Diabetes Metab Syndr
N Eant, Lingas, Hingrat, Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort, Proc Natl Acad Sci U S A
Parienti, Prazuck, Peyro-Saint-Paul, Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial, EClinicalMedicine
Perico, Ostermann, Bontempeill, Colchicine interferes with L-selectin and leukocyte function-associated antigen-1 expression on human T lymphocytes and inhibits T cell activation, J Am Soc Nephrol
Permana, Huang, Purwiga, In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis, Pharmacol Rep
R€ Ucker, Schwarzer, Ranking treatments in frequentist network meta-analysis works without resampling methods, BMC Med Res Methodol
Saavedra-Trujillo, Consenso Colombiano de atenci on, diagn ostico y manejo de la infecci on por SARS-COV-2/COVID-19 en establecimientos de atenci on de la salud: recomendaciones basadas en consenso de expertos e informadas en la evidencia ACIN-IETS
Schwartz, Lellouch, Explanatory and pragmatic attitudes in therapeutical trials, J Clin Epidemiol
Siemieniuk, Bartoszko, Ge, Drug treatments for covid-19: living systematic review and network meta-analysis, BMJ
Takemoto, Liao, Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, Arterioscler Thromb Vasc Biol
Tardif, Bouabdallaoui, Allier, Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, Lancet Respir Med
Vahedian-Azimi, Mohammadi, Beni, Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: a systematic review and meta-analysis, Arch Med Sci
Varga, Flammer, Steiger, Endothelial cell infection and endotheliitis in COVID-19, Lancet
Vickerstaff, Omar, Ambler, Methods to adjust for multiple comparisons in the analysis and sample size calculation of randomised controlled trials with multiple primary outcomes, BMC Med Res Methodol
Vitiello, Ferrara, Colchicine and SARS-CoV-2: Management of the hyperinflammatory state, Respir Med
Wang, Zhang, Du, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet
Who, Pan, Peto, Repurposed Antiviral Drugs for Covid-19 -Interim WHO Solidarity Trial Results, N Engl J Med
Wilson, Runciman, Gibberd, Harrison, Newby et al., The Quality in Australian Health Care Study, Med J Aust
Xing, Tu, Liu, Efficacy and safety of COVID-19 vaccines: a systematic review, Zhongguo Dang Dai Er Ke Za Zhi
Zhang, Bastard, Liu, Inborn errors of type I IFN immunity in patients with life-threatening COVID-19, Science
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop